DMAA · Drugs Made In America Acquisition Corp.
$10.75
+0.03 (+0.23%)
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Additionally, the date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company's ability to continue as a going concern. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. Management plans to address this uncertainty through a Business Combination. There is no assurance that the Company's plans to raise capital or to consummate a Business Combination will be successful within the Combination Period.”View the 10-Q filed Aug 14, 2026
Market Cap
$260.98M
Shares
24.28M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.75
Open$10.73
Day$10.73–10.75
52W close$10.25–10.75
Avg vol 30d44K
Short int89K · 0.4% float · 5.1d
Short vol1%
DataFeb 2025–Aug 2026
Filing10-Q · Aug 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very Low
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
+1%
above
RSI (14)
77
overbought
MACD trend
Positive
52-week position
100%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+3%
trailing
YTD return
+4%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow
Distributing
-19% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.37% of float · ▼ -5.6% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
42 holders — mid 1-yr range
Squeeze score
49
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
2%
annualized · 1-yr
Max drawdown
0%
past year
ATR
0.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
77
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow
Distributing
-19% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.37% of float · ▼ -5.6% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
42 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $10
Now $11 · 100%
Range high $11
vs 200-day avg +3%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DMAA
this stock
Drugs Made In America Acquisition Corp.
|
$260.98M | +3.6% | — | — | 0.4% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
CCXI
Churchill Capital Corp XI
|
$811.55M | — | — | — | 3.8% |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$645.92M | +2.4% | — | — | 0.2% |
|
BCSS
Bain Capital GSS Investment Corp.
|
$600.35M | +2.0% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DMAA | +0.4% | +0.8% | +3.0% | +0.4% | +3.6% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +1.7% | -2.8% | -8.6% | -2.1% | -8.7% |
Key facts
CIK
2028614
CUSIP
G2847J104
13F (30d)
46 filings
43 filers